European Journal of Heart Failure

FEBRUARY 5, 2025

Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis. Abstract Aims Angiotensin receptorneprilysin inhibitor (ARNI) has played an increasingly important role in the management of heart failure (HF).

Kidney Disease 49

Kidney Disease Heart Failure Preserved Ejection Fraction Blood Pressure 49

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

DAIC

JANUARY 19, 2024

AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure. This leaves a gap in the care of these patients and increases their risk for heart attack, stroke and heart failure progression.

Pacemaker 105

Pacemaker Hypertension Blood Pressure Kidney Disease 105

Journal of the American Heart Association

MARCH 18, 2024

Classically, activation of the MR in the renal tubular epithelium is responsible for sodium retention and volume expansion, raising systemic blood pressure.

Blood Pressure 40

Blood Pressure Kidney Disease Heart Failure Outcomes 40

Circulation

NOVEMBER 11, 2024

Introduction:Smoking is a well-known risk factor for atherosclerotic cardiovascular disease and kidney failure among patients with chronic kidney disease (CKD). However, the association of former and current smoking status (vs.

Kidney Disease 40

Kidney Disease Heart Failure Blood Pressure Public Health 40

Cardiometabolic Health Congress

NOVEMBER 16, 2023

Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.

Kidney Disease 52

Kidney Disease Blood Pressure Diabetes Hospital 52

Circulation

JANUARY 24, 2024

METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.

Heart Disease 81

Heart Disease Peripheral Arterial Disease Strokes Stroke 81

Circulation

NOVEMBER 11, 2024

Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidney disease and heart failure. vs 5.4%), and hospitalization for heart failure (RR 0.66; 95% CI [0.58, 0.76]; P < 0.00001; 3.2%

Myocardial Infarction 40

Myocardial Infarction Blood Pressure Heart Failure Kidney Disease 40

Circulation

NOVEMBER 11, 2024

Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among Results:Among 5002 (projected to 34.0

Diabetes 40

Diabetes Blood Pressure Myocardial Infarction Kidney Disease 40

Circulation

NOVEMBER 11, 2024

Introduction:High levels of blood pressure (BP) are responsible for 7.6 The diagnosis of hypertension is associated with a significant increase in the risk of kidney or cardiovascular events, with no prior history of these events. The AAMR for hypertensive heart and renal disease with heart failure was 0.1

Hypertension 40

Hypertension Heart Failure Certification Kidney Disease 40

DAIC

DECEMBER 8, 2023

AFib causes a variety of symptoms, including fast or chaotic heartbeat, fatigue, shortness of breath, and chest pain, and causes about 450,000 hospitalizations each year, according to the Centers for Disease Control and Prevention. For example, kidney disease is not included in CHA 2 DS 2 -VASc.

Atrial Fibrillation 52

Atrial Fibrillation AFIB Strokes Stroke 52

Physiologically Speaking

DECEMBER 15, 2023

Effects of resistance training on traditional CVD risk factors Blood pressure Resistance exercise training has been shown to improve resting blood pressure in cohorts of healthy adults and adults with varying levels of high blood pressure.

Physiology 52

Physiology Exercise Blood Pressure Risk Factors 52

Physiologically Speaking

DECEMBER 15, 2023

Effects of resistance training on traditional CVD risk factors Blood pressure Resistance exercise training has been shown to improve resting blood pressure in cohorts of healthy adults and adults with varying levels of high blood pressure.

Physiology 52

Physiology Exercise Blood Pressure Risk Factors 52

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Cardiometabolic Health Congress

DECEMBER 7, 2023

AF is associated with an increased risk of death as well as multiple adverse outcomes, including stroke, cognitive impairment or dementia, myocardial infarction, sudden cardiac death, heart failure (HF), chronic kidney disease (CKD), and peripheral artery disease (PAD).

Atrial Fibrillation 111

Atrial Fibrillation Risk Factors Ablation Strokes 111

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. In the U.S.,

CME 103

CME Obesity Heart Failure Biomarkers 103

Frontiers in Cardiovascular Medicine

JANUARY 5, 2025

IntroductionVericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7) 7,054.0)] pg/ml.

Heart Failure 52

Heart Failure Kidney Disease Blood Pressure Diabetes 52